Ad
Wednesday, 18 October 2017
Astra and Merck win speedy review for Lynparza in breast cancer
LONDON (Reuters) - U.S. regulators have granted a priority review to AstraZeneca's ovarian cancer drug Lynparza as a treatment for breast cancer, putting it on track for potential approval in the new disease area during the first quarter of 2018.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment